ATE501126T1 - Verfahren zur herstellung von rosuvastatin - Google Patents
Verfahren zur herstellung von rosuvastatinInfo
- Publication number
- ATE501126T1 ATE501126T1 AT02781613T AT02781613T ATE501126T1 AT E501126 T1 ATE501126 T1 AT E501126T1 AT 02781613 T AT02781613 T AT 02781613T AT 02781613 T AT02781613 T AT 02781613T AT E501126 T1 ATE501126 T1 AT E501126T1
- Authority
- AT
- Austria
- Prior art keywords
- producing rosuvastatin
- rosuvastatin
- producing
- preparation
- relates
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title 1
- 229960000672 rosuvastatin Drugs 0.000 title 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 229960004796 rosuvastatin calcium Drugs 0.000 abstract 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/535—Organo-phosphoranes
- C07F9/5352—Phosphoranes containing the structure P=C-
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2002/005213 WO2004052867A1 (en) | 2002-12-10 | 2002-12-10 | Process for the preparation of rosuvastatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE501126T1 true ATE501126T1 (de) | 2011-03-15 |
Family
ID=32500442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02781613T ATE501126T1 (de) | 2002-12-10 | 2002-12-10 | Verfahren zur herstellung von rosuvastatin |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7566782B2 (https=) |
| EP (1) | EP1578733B1 (https=) |
| CN (1) | CN1742000A (https=) |
| AT (1) | ATE501126T1 (https=) |
| AU (1) | AU2002348881A1 (https=) |
| CA (1) | CA2509619A1 (https=) |
| DE (1) | DE60239428D1 (https=) |
| DK (1) | DK1578733T3 (https=) |
| HU (1) | HUP0500851A3 (https=) |
| SI (1) | SI1578733T1 (https=) |
| WO (1) | WO2004052867A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL159741A0 (en) | 2001-07-13 | 2004-06-20 | Astrazeneca Uk Ltd | Preparation of aminopyrimidine compounds |
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| WO2005023778A2 (en) | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| EP1601658A1 (en) | 2003-11-24 | 2005-12-07 | Teva Pharmaceutical Industries Limited | Crystalline ammonium salts of rosuvastatin |
| US7244844B2 (en) | 2003-12-02 | 2007-07-17 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
| WO2006017357A1 (en) | 2004-07-13 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step |
| GB0428328D0 (en) * | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
| KR101020024B1 (ko) | 2005-02-22 | 2011-03-09 | 테바 파마슈티컬 인더스트리즈 리미티드 | 로수바스타틴 알킬에테르를 함유하지 않는 로수바스타틴 및이의 염 및 이의 제조 방법 |
| WO2006100689A1 (en) * | 2005-03-22 | 2006-09-28 | Unichem Laboratories Limited | Process for preparation of rosuvastatin |
| WO2006106526A1 (en) * | 2005-04-04 | 2006-10-12 | Unichem Laboratories Limited | Process for preparation of calcium salt of rosuvastatin |
| CN1307187C (zh) * | 2005-05-16 | 2007-03-28 | 浙江海正药业股份有限公司 | 瑞舒伐他汀及其中间体的制备方法 |
| EP1893585A1 (en) * | 2005-06-01 | 2008-03-05 | Fermion Oy | Process for the preparation of n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide |
| US9150518B2 (en) | 2005-06-24 | 2015-10-06 | Lek Pharmaceuticals, D.D. | Process for preparing amorphous rosuvastatin calcium of impurities |
| CZ299215B6 (cs) * | 2005-06-29 | 2008-05-21 | Zentiva, A. S. | Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny |
| WO2007022488A2 (en) | 2005-08-16 | 2007-02-22 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin intermediate |
| CA2625290A1 (en) * | 2005-10-04 | 2007-04-12 | Teva Pharmaceutical Industries Ltd. | Preparation of rosuvastatin |
| US8318933B2 (en) | 2006-10-31 | 2012-11-27 | Aurobindo Pharma Ltd | Process for preparing rosuvastatin calcium |
| WO2008072078A1 (en) * | 2006-12-13 | 2008-06-19 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin caclium |
| ES2385623T3 (es) | 2007-02-08 | 2012-07-27 | Aurobindo Pharma Limited | Un procedimiento mejorado para la preparación de rosuvastatina cálcica |
| US20090069563A1 (en) * | 2007-07-12 | 2009-03-12 | Valerie Niddam-Hildesheim | Rosuvastatin intermediates and their preparation |
| KR101157314B1 (ko) | 2009-06-05 | 2012-06-15 | 주식회사종근당 | 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법 |
| EP2336116A1 (en) | 2009-12-16 | 2011-06-22 | LEK Pharmaceuticals d.d. | Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof |
| JP5822169B2 (ja) * | 2010-07-01 | 2015-11-24 | ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ | ＨＭＧ−ＣｏＡ還元酵素阻害剤及びその中間体の製造方法 |
| WO2012011129A2 (en) * | 2010-07-22 | 2012-01-26 | Msn Laboratories Limited | Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt |
| HU230987B1 (hu) | 2010-11-29 | 2019-08-28 | Egis Gyógyszergyár Nyrt. | Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására |
| CA2835364C (en) * | 2011-05-20 | 2018-10-02 | Astrazeneca Uk Limited | Pharmaceutical composition of rosuvastatin calcium |
| CN102358747B (zh) * | 2011-08-30 | 2012-09-19 | 浙江宏元药业有限公司 | 瑞舒伐他汀钙中间体及制备瑞舒伐他汀钙中间体和瑞舒伐他汀钙的方法 |
| WO2015074328A1 (zh) * | 2013-11-25 | 2015-05-28 | 复旦大学 | 一种瑞舒伐他汀钠的制备方法 |
| CN103601687A (zh) * | 2013-11-25 | 2014-02-26 | 复旦大学 | 一种瑞舒伐他汀钠的制备方法 |
| CN104230990B (zh) * | 2014-08-15 | 2016-05-11 | 新发药业有限公司 | 2-((4r,6s)-6-三苯基膦烯甲叉基-2,2-二取代基-1,3-二氧六环-4-基)乙酸酯及其制备方法与应用 |
| CN104630297B (zh) * | 2014-12-10 | 2018-07-06 | 江南大学 | 一种酶法非水相催化合成(r)-3-tbdmso戊二酸甲单酯及其衍生物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
-
2002
- 2002-12-10 AT AT02781613T patent/ATE501126T1/de active
- 2002-12-10 EP EP02781613A patent/EP1578733B1/en not_active Expired - Lifetime
- 2002-12-10 CA CA002509619A patent/CA2509619A1/en not_active Abandoned
- 2002-12-10 DK DK02781613.1T patent/DK1578733T3/da active
- 2002-12-10 CN CNA028301951A patent/CN1742000A/zh active Pending
- 2002-12-10 DE DE60239428T patent/DE60239428D1/de not_active Expired - Lifetime
- 2002-12-10 SI SI200230942T patent/SI1578733T1/sl unknown
- 2002-12-10 WO PCT/IB2002/005213 patent/WO2004052867A1/en not_active Ceased
- 2002-12-10 AU AU2002348881A patent/AU2002348881A1/en not_active Abandoned
- 2002-12-10 US US10/537,859 patent/US7566782B2/en not_active Expired - Fee Related
- 2002-12-10 HU HU0500851A patent/HUP0500851A3/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7566782B2 (en) | 2009-07-28 |
| WO2004052867A1 (en) | 2004-06-24 |
| CN1742000A (zh) | 2006-03-01 |
| SI1578733T1 (sl) | 2011-07-29 |
| HUP0500851A3 (en) | 2008-02-28 |
| US20060149065A1 (en) | 2006-07-06 |
| CA2509619A1 (en) | 2004-06-24 |
| AU2002348881A1 (en) | 2004-06-30 |
| EP1578733B1 (en) | 2011-03-09 |
| DK1578733T3 (da) | 2011-06-14 |
| EP1578733A1 (en) | 2005-09-28 |
| DE60239428D1 (https=) | 2011-04-21 |
| HUP0500851A2 (en) | 2007-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE501126T1 (de) | Verfahren zur herstellung von rosuvastatin | |
| ATE501125T1 (de) | Verfahren zur herstellung des calciumsalzes von rosuvastatin | |
| DE502004009142D1 (de) | Verfahren zur herstellung substituierter 3-aryl-butyl-aminverbindungen | |
| ATE489365T1 (de) | Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-6,6-dimethyl-3-azabicycloä3,1,0 ühexan-2-carboxylaten oder salzen davon | |
| DE60323749D1 (de) | Substituierte pyrroline als kinase inhibitoren | |
| ATE360653T1 (de) | Verfahren zur herstellung von polyisobutenen | |
| EP1601809A4 (en) | PROCESS FOR PRODUCING BIPHASED TOLE | |
| ATE370150T1 (de) | Verfahren zur herstellung von salzen schwach koordinierender aniomen, derartige salze sowie deren verwendung | |
| DE60311990D1 (de) | Verfahren zur herstellung eines virus inaktivierten thrombin präparates | |
| ATE387425T1 (de) | Verfahren zur herstellung von bicalutamid | |
| ATE489352T1 (de) | Verfahren zur herstellung von brenztraubensäure | |
| WO2006066044A3 (en) | Processes for producing 4-aminoquinazolines | |
| ATE528280T1 (de) | Verfahren zur herstellung von triethanolamin | |
| DE50110561D1 (de) | Non-metallocene, verfahren zur herstellung von diesen und deren verwendung zur polymerisation von olefinen | |
| ATE272038T1 (de) | Verfahren zur herstellung von 2-alkyl-3- chlorphenolen | |
| ATE370950T1 (de) | Verfahren zur herstellung von (1s,4r)-cis-4-(2- amino-6-chlor-9h-purin-9-yl)-2-cyclopenten-1- methanol | |
| MXPA05011013A (es) | Procedimiento para preparar la fenilamida del acido 5-(4-fluorofenil) -1-[2- ((2r, 4r)- 4-hidroxi-6 -oxo-tetrahidropiran -2-il) etil]-2 -isopropil-4 -fenil-1h- pirrol -3-carboxilico. | |
| ATE549315T1 (de) | Verfahren zur herstellung von kristallinem perindopril | |
| ATE318815T1 (de) | Verfahren zur herstellung von enantiomeren von indol-2,3-dion-3-oximderivaten | |
| ATE517890T1 (de) | Verfahren zur herstellung von reinem irbesartan | |
| ATE380183T1 (de) | Verfahren zur herstellung von phenyltetrazolderivaten | |
| ATE425143T1 (de) | Verfahren zur herstellung von indolen | |
| ATE297404T1 (de) | Verbessertes verfahren zur herstellung von bisphosphiten | |
| DE602005007724D1 (de) | Verfahren zur halbsynthese von deserpidin | |
| ATE325111T1 (de) | Verfahren zur herstellung von 15-pentadecanolid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1578733 Country of ref document: EP |